KR100750553B1 - 외분비 장애 치료용 조성물 - Google Patents

외분비 장애 치료용 조성물 Download PDF

Info

Publication number
KR100750553B1
KR100750553B1 KR1020027000471A KR20027000471A KR100750553B1 KR 100750553 B1 KR100750553 B1 KR 100750553B1 KR 1020027000471 A KR1020027000471 A KR 1020027000471A KR 20027000471 A KR20027000471 A KR 20027000471A KR 100750553 B1 KR100750553 B1 KR 100750553B1
Authority
KR
South Korea
Prior art keywords
ether
ester
salt
delete delete
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027000471A
Other languages
English (en)
Korean (ko)
Other versions
KR20020060149A (ko
Inventor
우에노류지
Original Assignee
수캄포 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수캄포 아게 filed Critical 수캄포 아게
Publication of KR20020060149A publication Critical patent/KR20020060149A/ko
Application granted granted Critical
Publication of KR100750553B1 publication Critical patent/KR100750553B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020027000471A 1999-07-14 2000-07-13 외분비 장애 치료용 조성물 Expired - Fee Related KR100750553B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14362799P 1999-07-14 1999-07-14
US60/143,627 1999-07-14

Publications (2)

Publication Number Publication Date
KR20020060149A KR20020060149A (ko) 2002-07-16
KR100750553B1 true KR100750553B1 (ko) 2007-08-20

Family

ID=22504885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027000471A Expired - Fee Related KR100750553B1 (ko) 1999-07-14 2000-07-13 외분비 장애 치료용 조성물

Country Status (25)

Country Link
US (3) US6566398B1 (cg-RX-API-DMAC7.html)
EP (1) EP1223925B1 (cg-RX-API-DMAC7.html)
JP (2) JP4167828B2 (cg-RX-API-DMAC7.html)
KR (1) KR100750553B1 (cg-RX-API-DMAC7.html)
CN (4) CN101695495A (cg-RX-API-DMAC7.html)
AR (2) AR029381A1 (cg-RX-API-DMAC7.html)
AT (1) ATE344027T1 (cg-RX-API-DMAC7.html)
AU (1) AU779936B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0012387B1 (cg-RX-API-DMAC7.html)
CA (1) CA2377661C (cg-RX-API-DMAC7.html)
CZ (1) CZ303958B6 (cg-RX-API-DMAC7.html)
DE (1) DE60031710T2 (cg-RX-API-DMAC7.html)
DK (1) DK1223925T3 (cg-RX-API-DMAC7.html)
ES (1) ES2273706T3 (cg-RX-API-DMAC7.html)
HK (1) HK1048443B (cg-RX-API-DMAC7.html)
HU (1) HU229318B1 (cg-RX-API-DMAC7.html)
IL (2) IL147440A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02000437A (cg-RX-API-DMAC7.html)
NO (1) NO323908B1 (cg-RX-API-DMAC7.html)
PT (1) PT1223925E (cg-RX-API-DMAC7.html)
RU (1) RU2264816C2 (cg-RX-API-DMAC7.html)
TR (1) TR200200065T2 (cg-RX-API-DMAC7.html)
TW (1) TWI225398B (cg-RX-API-DMAC7.html)
WO (1) WO2001005388A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200109726B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
WO2003105823A1 (en) * 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth
US20040076695A1 (en) * 2002-07-08 2004-04-22 Advanced Vision Research EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
US20040185075A1 (en) 2003-01-31 2004-09-23 Maria Dalko Use of at least one (dihydro)jasmonic acid derivative for treating dry skin
FR2850571B1 (fr) * 2003-01-31 2006-07-07 Oreal Utilisation d'un derive d'acide(dihydro) jasmonique pour le traitement des peaux seches
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CA2541302A1 (en) 2003-10-06 2005-04-14 Ophtecs Corporation Ophthalmic composition for treating tear dysfunction
US7923471B2 (en) 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
AU2005262392A1 (en) * 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
JP5147404B2 (ja) * 2005-01-27 2013-02-20 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
AU2006219152B2 (en) * 2005-03-04 2011-02-24 Sucampo Ag Method and composition for treating peripheral vascular diseases
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
BRPI0707333B8 (pt) 2006-01-24 2021-05-25 R Tech Ueno Ltd composição farmacêutica que compreende um composto bicíclico, método de estabilização do composto bicíclico e formulação de cápsula de gelatina mole
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US9161909B2 (en) 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US9884082B2 (en) 2008-11-13 2018-02-06 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9597278B2 (en) 2008-11-13 2017-03-21 David A. Hamlin Compositions and methods for alleviating hyposalivation and for providing oral comfort
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US8918181B2 (en) 2010-11-16 2014-12-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
CA2842455A1 (en) * 2011-08-05 2013-02-14 Sucampo Ag Method for treating schizophrenia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CN108744272A (zh) 2013-04-19 2018-11-06 奥库利维公司 鼻刺激装置和方法
KR20170074926A (ko) * 2014-10-22 2017-06-30 오큘레브, 인크. 안구 건조증을 치료하기 위한 자극 장치 및 방법
US10918864B2 (en) 2016-05-02 2021-02-16 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
WO2019208435A1 (ja) 2018-04-26 2019-10-31 ライオン株式会社 外分泌促進剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0019423A1 (en) * 1979-05-18 1980-11-26 Efamol Limited Pharmaceutical and dietary composition comprising gamma-linolenic acids
EP0132089A1 (en) * 1983-07-14 1985-01-23 Scotia Holdings Plc Fatty acid compositions
WO1997016179A1 (en) * 1995-10-31 1997-05-09 Alcon Laboratories, Inc. Compositions containing hydroperoxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
JPH07103096B2 (ja) * 1987-01-28 1995-11-08 株式会社上野製薬応用研究所 プロスタグランジンd類およびそれを含む鎮静・睡眠剤
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンe類およびそれを含む抗潰瘍剤
DE3711164A1 (de) 1987-04-02 1988-10-20 Zeiss Carl Fa Steckelementeinrichtung zur halterung von bauteilen in stapeln
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
JPS63277604A (ja) * 1987-05-11 1988-11-15 Showa Denko Kk α−リノレン酸含有化粧料
JPH0692305B2 (ja) * 1987-05-15 1994-11-16 株式会社上野製薬応用研究所 体温上昇剤
GB2209939B (en) * 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
SU1673123A1 (ru) * 1987-12-04 1991-08-30 Научно-исследовательский институт морфологии человека АМН СССР Способ лечени болезни и синдрома Шегрена
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体
WO1990001323A1 (en) 1988-08-12 1990-02-22 Bernstein Joel E Method and composition for treating and preventing dry skin disorders
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
TW249226B (cg-RX-API-DMAC7.html) * 1990-04-04 1995-06-11 Aderk Ueno Kk
JPH07100655B2 (ja) * 1990-04-04 1995-11-01 株式会社アールテック・ウエノ 白内障処置剤
DE69130586T2 (de) * 1990-05-01 1999-06-17 R-Tech Ueno, Ltd., Osaka Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
JPH07113012B2 (ja) * 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規15−ケト−プロスタグランジン類
ATE141794T1 (de) * 1991-03-14 1996-09-15 R Tech Ueno Ltd Stimulierung von wundheilung mit 15-keto- prostaglandinverbindungen
US5369127A (en) 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
WO2000038690A2 (en) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
JP5147404B2 (ja) * 2005-01-27 2013-02-20 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
AU2006219152B2 (en) * 2005-03-04 2011-02-24 Sucampo Ag Method and composition for treating peripheral vascular diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0019423A1 (en) * 1979-05-18 1980-11-26 Efamol Limited Pharmaceutical and dietary composition comprising gamma-linolenic acids
EP0132089A1 (en) * 1983-07-14 1985-01-23 Scotia Holdings Plc Fatty acid compositions
WO1997016179A1 (en) * 1995-10-31 1997-05-09 Alcon Laboratories, Inc. Compositions containing hydroperoxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders

Also Published As

Publication number Publication date
AR074465A2 (es) 2011-01-19
TR200200065T2 (tr) 2002-10-21
AR029381A1 (es) 2003-06-25
HUP0202400A2 (hu) 2002-11-28
MXPA02000437A (es) 2004-05-21
AU5853300A (en) 2001-02-05
WO2001005388A2 (en) 2001-01-25
IL147440A0 (en) 2002-08-14
WO2001005388A3 (en) 2002-05-10
US20050090556A1 (en) 2005-04-28
DK1223925T3 (da) 2007-03-19
ATE344027T1 (de) 2006-11-15
ES2273706T3 (es) 2007-05-16
CN101829120A (zh) 2010-09-15
HUP0202400A3 (en) 2005-02-28
DE60031710T2 (de) 2007-09-06
TWI225398B (en) 2004-12-21
EP1223925A2 (en) 2002-07-24
ZA200109726B (en) 2002-08-30
IL147440A (en) 2008-11-03
JP5052423B2 (ja) 2012-10-17
CZ303958B6 (cs) 2013-07-17
CA2377661C (en) 2012-05-08
HK1048443A1 (en) 2003-04-04
JP2003504397A (ja) 2003-02-04
KR20020060149A (ko) 2002-07-16
BRPI0012387B1 (pt) 2016-11-08
EP1223925B1 (en) 2006-11-02
CZ2002133A3 (cs) 2002-06-12
US20030171438A1 (en) 2003-09-11
JP2009007360A (ja) 2009-01-15
CN101829120B (zh) 2013-09-18
US7396946B2 (en) 2008-07-08
US6566398B1 (en) 2003-05-20
RU2264816C2 (ru) 2005-11-27
NO323908B1 (no) 2007-07-16
AU779936B2 (en) 2005-02-17
HK1048443B (en) 2007-06-08
DE60031710D1 (de) 2006-12-14
BR0012387A (pt) 2002-03-26
CN1399548A (zh) 2003-02-26
NO20020133L (no) 2002-03-13
NO20020133D0 (no) 2002-01-11
PT1223925E (pt) 2007-01-31
JP4167828B2 (ja) 2008-10-22
CN1915971A (zh) 2007-02-21
CA2377661A1 (en) 2001-01-25
CN101695495A (zh) 2010-04-21
CN100548977C (zh) 2009-10-14
HU229318B1 (hu) 2013-10-28

Similar Documents

Publication Publication Date Title
JP5052423B2 (ja) 外分泌障害処置剤
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
BRPI0317740B1 (pt) uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
JP2004504350A (ja) 高眼圧症および緑内障処置用組成物
AU2001239551B8 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
JP2010519177A (ja) ミトコンドリアを保護するための組成物および方法
JP2004538306A (ja) 高眼圧症および緑内障の処置
CA2870252A1 (en) Method for treating irritable bowel syndrome with diarrhea
AU2002355693A1 (en) Treatment of ocular hypertension and glaucoma
EP0410646B1 (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20130703

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20140704

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20150624

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20160623

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20170627

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20180806

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190814

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190814